{"url_path":"/sec/aktx/10-q/2026/item-1a","section_key":"item-1a","section_title":"Item 1A Risk Factors.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-19","source_url":"https://www.sec.gov/Archives/edgar/data/1541157/0001493152-26-024446-index.html","accession_number":"0001493152-26-024446","cik":"0001541157","ticker":"AKTX","issuer_name":"Akari Therapeutics Plc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1541157/0001493152-26-024446-index.html","primary_entity_key":"0001541157","primary_entity_name":"Akari Therapeutics Plc"},"word_count":344,"has_tables":true,"body_markdown":"**Item\n1A. Risk Factors.**\n\n** **\n\nInvesting\nin our securities involves a high degree of risk. You should carefully consider the risks and uncertainties discussed within *“Item\n1A. Risk Factors”* of our Form 10-K, together with all of the other information in this Form 10-Q, including the section “Management’s\nDiscussion and Analysis of Financial Condition and Results of Operations” and our unaudited condensed consolidated financial statements\nand related notes, before deciding whether to purchase any of our ADSs.\n\n \n\n*We\nhave IPR&D and future impairment of IPR&D may have an adverse impact on our future financial condition and results of operations.*\n\n* *\n\nAs of March 31, 2026,\nwe had in-process research and development (“IPR&D”) of approximately $30.3 million, primarily relating to AKTX-101 and\nour ADC Platform. Our intangible assets have been previously impaired and remain subject to additional impairment analyses whenever an\nevent or change in circumstances indicates the carrying amount of such an asset may not be recoverable. Events giving rise to impairment\nare difficult to predict and are an inherent risk in the pharmaceutical industry. Some of the potential risks that could result in further\nimpairment of our IPR&D include negative preclinical or clinical trial results, adverse regulatory developments, delay or failure\nto obtain regulatory approval, additional development costs, changes in the manner of our use or development of our product candidates,\ncompetition, earlier than expected loss of exclusivity, pricing pressures, higher operating costs, our inability to identify or enter\ninto strategic partnerships, collaborations or out-licensing arrangements on acceptable terms or at all, geopolitical conflicts, changes\nin tax laws, prices that third parties are willing to pay for our IPR&D or similar assets in an arm’s length transaction being\nless than the carrying value of our IPR&D, declines in our market capitalization, and other adverse market and economic environment\nchanges or trends. Any and all of these conditions are reasonably likely to exist in the future and materialization of these risks or\nother changes in circumstances may lead to significant impairment charges on our IPR&D in the future, which could materially\nadversely affect our financial results."}